Samsung Bioepis and Teva expand biosimilars partnership to up to six candidates
Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.
The initial assets are SB41, a proposed biosimilar to Fasenra, and SB44, a proposed biosimilar to Ilaris, with Samsung Bioepis leading development and manufacturing.
Teva will contribute commercial capabilities across the US, Europe and Canada, creating a multi-product platform spanning major immunology and inflammatory-disease markets.
Field | Content |
Article Type | Deals |
Companies | Samsung Bioepis; Teva Pharmaceuticals |
Deal Type | Strategic biosimilars development and commercialisation partnership |
Initial Assets | SB41; SB44 |
Reference Products | Fasenra; Ilaris |
Programme Scope | Two named biosimilars plus options for up to four additional candidates |
Therapy Areas | Immunology; inflammatory disease |
Technology/Modality | Monoclonal antibody biosimilars |
Development Responsibilities | Samsung Bioepis will lead development, regulatory activities and manufacturing |
Commercial Responsibilities | Teva will contribute commercial infrastructure in agreed markets |
Core Markets | United States; Europe; Canada |
What Happened | Samsung Bioepis and Teva expanded their strategic partnership to cover up to six potential biosimilar candidates. |
Why It Matters | The agreement creates a sizeable multi-asset biosimilars collaboration spanning major biologic markets and multiple geographies. |
Strategic Rationale | Samsung Bioepis contributes biosimilar development and manufacturing expertise while Teva provides established commercial infrastructure. |
Potential Impact | The partnership could increase biosimilar competition across high-value immunology and inflammatory-disease products. |
Key Takeaway | Samsung Bioepis and Teva are building a biosimilars portfolio of up to six candidates, starting with proposed Fasenra and Ilaris biosimilars. |
What to Watch | Regulatory development of SB41 and SB44 and selection of the four optional additional candidates. |
Primary Source | Samsung Bioepis |
Relevant Date | 1 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글